TOI today
$5.13+$0.27 (+5.56%)close Aug 3, 2026Trend
DailyDowntrend (starting)
4 hourBullish
1 hourExpanding
15 minBullish
5 minNo data
Daily trend turns up above $6.67
Key levels
Resistance$5.59
Resistance$5.19
Support$4.70
Support$4.22
Latest news & SEC filings
SEC FilingStarling Oncology, Inc. filed an insider trading report (Form 4)
DealTopicus.com unit closes purchase of Softland Inversiones
All TOI news →Nasdaq · Other
Starling Oncology, Inc. (TOI)
What Is the Price Target for TOI?
SEPT Low Target
$6.80
SEPT Mid Target
$8.00
SEPT High Target
$9.20
Analyst Consensus
$8.00
Is TOI a Buy or Sell Right Now?
Thesis
- •Revenue growing 27.8% YoY with ACCELERATING trend — accelerating momentum.
- •Smart money flows are positive — institutional and insider activity shows net buying.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for TOI.
Start Free Trial →Is TOI Overvalued or Undervalued?
Valuation Verdict
FAIR
Methods Used
PEG, Analyst Consensus
Fair Value
$6.70
44
Moat Score
NARROW
3/9
Piotroski Score
2.0
Altman Z-Score
What Is Smart Money Doing with TOI?
Insider Signal
BUYING
6 buys / 3 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
DISTRIBUTING
Short Squeeze Risk
LOW
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Podnos Yale | officer | Sale | 23,451 | $126K | Jun 8, 2026 |
| Chernett Jorey | 10% owner | Buy | 12,000 | $57K | Jun 4, 2026 |
| Podnos Yale | officer | Sale | 1,805 | $8K | May 21, 2026 |
| Virnich Daniel | officer | Sale | 23,058 | $103K | May 21, 2026 |
| Carter Robert Ross | officer | Sale | 1,604 | $7K | May 21, 2026 |
| Chernett Jorey | 10% owner | Buy | 33,500 | $136K | May 20, 2026 |
| Chernett Jorey | 10% owner | Buy | 30,000 | $123K | May 19, 2026 |
| Chernett Jorey | 10% owner | Buy | 5,000 | $20K | May 19, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →TOI Growth Story
Revenue YoY
27.8%
3yr Revenue CAGR
N/A%
EPS Growth YoY
23.94%
FCF Growth YoY
8.4%
Revenue Trend
ACCELERATING
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Starling Oncology, Inc. (TOI) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (2 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →TOI — frequently asked questions
What is TOI stock price today?
Starling Oncology, Inc. (TOI) is at $5.13, up 5.56% (+$0.27) at the Aug 3, 2026 close.
Why is TOI stock moving today?
Latest TOI news — Nov 12, 2026: Starling Oncology, Inc. filed an insider trading report (Form 4) · Nov 6, 2026: Topicus.com unit closes purchase of Softland Inversiones
What is the TOI price target?
The average analyst price target for TOI is $8.00, ranging from $7 to $9, based on 2 analysts. Latest: BTIG maintains on Jul 9, 2026.
What do analysts rate TOI?
Analyst ratings for TOI: 0 Buy, 3 Hold, 0 Sell — consensus Hold.
Did TOI beat earnings?
TOI last reported on Aug 6, 2026: EPS -$0.08 vs -$0.06 expected — a miss of 33.3%.
Does TOI pay a dividend?
TOI does not currently pay a dividend.
What are TOI support and resistance levels?
Support: $4.70, $4.22, $3.71. Resistance: $5.19, $5.59, $6.11.
What are insiders doing with TOI?
Insider activity: BUYING, 6 buys and 3 sells in the last 90 days.
What is the latest news on TOI?
Nov 12, 2026: Starling Oncology, Inc. filed an insider trading report (Form 4) · Nov 6, 2026: Topicus.com unit closes purchase of Softland Inversiones